NovaBridge Biosciences

NASDAQ:NBP

Biotechnology

Healthcare
$0.90 -4.78%

-$0.07 today

Market cap
$104.10M
Beta
1.48
P/E (TTM)
-25.5
EPS (TTM)
-$0.40
52W Low $1.46High $6.79

Volume 0.87M

Average 0.90M

NBP Interest Expense

Cost of servicing the company's debt during the period.

NovaBridge BiosciencesNASDAQ: NBP

Interest Expense · Q4 FY2025 · quarter ended Dec 2025

Interest expense remains negative

Q4 FY2025 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $0.

Context

  • Interest expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2025
$0— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

Mixed currencies · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Expense vs competitors

How NBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
NBP Competitors
Interest Expense for NBP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$9.64M USD—-38.1%—
GALTGalectin Therapeutics Inc.LTM Mar 2026$7.57M USD+21.5%+92.2%—
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$4.73M USD+150.6%-0.3%—
ENGNenGene Holdings Inc.LTM Apr 2026$2.99M USD-0.3%+28.1%—
ALTAltimmune, Inc.LTM Mar 2026$2.7M USD+29933.3%+489.2%7508.3%
NBPNovaBridge BiosciencesLTM Sep 2025CN¥0 CNY———
AURAAura Biosciences, Inc.LTM Mar 2026$0 USD———
DSGNDesign Therapeutics, Inc.LTM Mar 2026$0 USD———
ANNXAnnexon, Inc.LTM Mar 2026$0 USD———
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$0 USD———
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026-$206.5K USD———
Peer median (excluding NBP) —+86.0%+28.1%7508.3%

Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CNY
FY2022
Dec 2022 · CNY
FY2023
Dec 2023 · CNY
FY2024
Dec 2024 · CNY
FY2025
Dec 2025 · USD
Revenue88.03M(10.7M)4.49M00
Cost of Revenue46.43M0000
Gross Profit41.59M(10.7M)4.49M00
Gross Margin47.3%100.0%100.0%——
Research & Development190.29M155.51M114.36M158.9M8.99M
Selling, General & Admin899.94M199.88M63.91M216.46M4.48M
Operating Expenses2.11B355.38M515.65M375.36M13.48M
Depreciation & Amortization13.78M1.42M3.37M1.91M122.37K
EBITDA(2.06B)(51.23M)(344.25M)(373.45M)(13.35M)
EBITDA Margin-2337.4%478.9%-7674.2%——
Operating Income(2.07B)(366.08M)(511.16M)(375.36M)(13.48M)
Operating Margin-2353.1%3422.2%-11395.1%——
Interest Income21.33M4.95M7.3M54.64M1.09M
Interest Expense00101.85K00
Other Income / Expenses(260.73M)(607.09M)(954.53M)12.63M847.61K
Income Before Tax(2.33B)(973.17M)(1.47B)(362.73M)(12.63M)
Pre-Tax Margin-2649.3%9097.4%-32674.0%——
Income Tax Expense(494.81K)710.39K(1.26B)00
Net Income(2.33B)(2.51B)(1.47B)(162.26M)(6.61M)
Net Margin-2648.7%23438.9%-32674.0%——
EPS (Basic)(30.70)(30.38)(17.62)(4.46)(0.16)
EPS (Diluted)(30.68)(30.38)(17.62)(4.46)(0.16)
Weighted Avg Shares75.93M82.52M83.19M81.19M41.64M
Weighted Avg Shares (Diluted)75.96M82.52M83.23M81.19M41.64M

NovaBridge Biosciences

NASDAQ:NBP

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.